Behavioral Variant Frontotemporal DementiaJT821NCT06761729
The Ketogenic Diet in the Treatment of Behavioral Variant Frontotemporal Dementia
A study testing Ketogenic diet in people with Behavioral Variant Frontotemporal Dementia, run by Xuanwu Hospital, Beijing.
Trial summary
This study is an exploratory clinical research on the use of JT821 (a ketogenic diet formulation) for the treatment of patients with behavioral variant frontotemporal dementia (bvFTD), aiming to evaluate the effectiveness, safety, and tolerability of JT821 in the intervention of bvFTD. Read more about this study
- Who is it for?
- Ages 45 to 70 years
- Conditions the study is for
- Behavioral Variant Frontotemporal Dementia
- What is being tested?
- Ketogenic diet
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 3 participants
- Where
- No sites listed yet
- Study dates
- 10 Feb 2025to 31 Oct 2025
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 45 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Subject is between the ages of 45 - 70;
- Meetting the diagnostic criteria for "probable bvFTD published by the International bvFTD Standards Consortium in 2011;
- Subjects must not undergo any drug adjustment treatment for 2 months prior to the enrollment and during the enrollment period ;
- Subjects must sign a written informed consent form prior to the screening visit examination. If the subject cannot sign due to limited cognitive ability or other reasons, the signature may be left blank, and the rationale must be stated. The legal guardian should provide the reason, sign the name, date, and time in the reason description area, and also sign the name, date, and time in the legal guardian column.
- Subject is between the ages of 45 - 70;
- Meetting the diagnostic criteria for "probable bvFTD published by the International bvFTD Standards Consortium in 2011;
- Subjects must not undergo any drug adjustment treatment for 2 months prior to the enrollment and during the enrollment period ;
- Subjects must sign a written informed consent form prior to the screening visit examination. If the subject cannot sign due to limited cognitive ability or other reasons, the signature may be left blank, and the rationale must be stated. The legal guardian should provide the reason, sign the name, date, and time in the reason description area, and also sign the name, date, and time in the legal guardian column.
Who cannot join
- Dementia caused by other factors: Alzheimer's Disease，vascular dementia, central nervous system infections (such as AIDS, syphilis, etc.), Huntington's disease and Parkinson's disease, Lewy body dementia, traumatic brain injury dementia, other physical and chemical factors (such as drug poisoning, alcohol poisoning, carbon monoxide poisoning, etc.), significant somatic diseases (such as hepatic encephalopathy, pulmonary etc.), intracranial space-occupying lesions (such as subdural hematoma, brain tumors), endocrine system disorders (such as thyroid diseases, parathyroid diseases) and dementia caused by vitamin deficiency or any other known causes;
- Having a low-carb diet , ketogenic diet, or vegan diet within 3 months before the screening visit or being currently doing.
- Patients diagnosed with schizophrenia spectrum disorder ,bipolar disorder, moderate to severe depression or delirium according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).
- Abnormal laboratory tests at screening visit and baseline: including liver function tests (alanine aminotransferase [ALT], aspartate aminotransferase [AST]) exceeding twice the upper limit of normal; and renal function (creatinine [Cr]) exceeding 1.5 times the upper limit of normal. Slight exceedances that are not clinically significance, as judged by the investigator, may not be excluded;
- Fasting triglycerides ≥ 5.7 mmol/L or total cholesterol ≥ 10.34 mmol/L at the screening visit and baseline;
- Presence any of the following infections at the screening visit:
Show all 33Show fewer
- Positive human immunodeficiency virus antibody (HIV Ab); Positive Treponema pallidum antibody (TP Ab);
- Gastrointestinal diseases that could affect the absorption or metabolism of the investigational product as judged by the investigator, within 2 months before the screening visit;
- Having undergone major surgeries deemed unsuitable for enrollment by the investigator within 6 months before the screening visit or those planning to undergo major surgeries during the study period (The definition of major surgeries refers to Grade 3 and Grade 4 surgeries as outlined in the "Administrative Measures for Grading of Surgeries in Medical Institutions (Trial)" implemented on December 6, 2022);
- Patients who have suffered from malignant tumors within 3 years prior to the screening visit (excluding basal cell carcinoma of the skin that has been radically cured, squamous cell carcinoma of the skin and/or carcinoma in situ that has been radically resected);
- Having a history of alcohol or drug abuse within 1 year prior to the screening visit;
- Known allergy to any components of the investigational product in this study;
- Having uncorrectable visual or auditory impairments or any other conditions that would affect the assessment of the scale;
- Contraindications to JT821:
- Absolute contraindications:
- Type 1 diabetes
- Primary carnitine deficiency (Laboratory tests: Hypoglycemia with low ketone levels, elevated creatine kinase (CK), etc.)
- Carnitine palmitoyl transferase (CPT) I and II deficiency (Laboratory tests: Hypoglycemia with low ketone levels, elevated transaminases, CK, elevated blood ammonia, tandem mass spectrometry for measurement of blood acylcarnitine profile, etc.)
- Carnitine translocase deficiency (Laboratory tests: Hypoglycemia with low ketone levels, elevated transaminases, CK, elevated blood ammonia, tandem mass spectrometry for measurement of blood acylcarnitine profile, etc.)
- β-Oxidation disorders (Laboratory tests: Blood glucose, electrolytes, blood lipids, coagulation, liver function, kidney function)
- Medium-chain acyl dehydrogenase deficiency (MCAD) (Laboratory tests: Hypoglycemia with low ketone levels, elevated transaminases, CK, elevated blood ammonia, metabolic acidosis, tandem mass spectrometry for measurement of blood acylcarnitine profile, etc.)
- Very long-chain acyl dehydrogenase deficiency (VLCAD) (Laboratory tests: Hypoglycemia with low ketone levels, elevated transaminases, CK, elevated creatine kinase isoenzyme (CK-MB) and lactate dehydrogenase (LDH), tandem mass spectrometry for measurement of blood acylcarnitine profile)
- Long-chain acyl dehydrogenase deficiency (LCAD) (Laboratory tests: Hypoglycemia with low ketone levels, elevated transaminases, CK, elevated creatine kinase isoenzyme (CK-MB) and lactate dehydrogenase (LDH), tandem mass spectrometry for measurement of blood acylcarnitine profile)
- Short-chain acyl dehydrogenase deficiency (SCAD) (Laboratory tests: Tandem mass spectrometry for measurement of blood acylcarnitine profile, determination of SCAD enzyme activity)
- Long-chain 3-hydroxyacyl-CoA deficiency (Laboratory tests: Hypoglycemia with low ketone levels, elevated transaminases, CK, elevated CK-MB and LDH, analysis of blood acylcarnitine profile, etc.)
- Medium-chain 3-hydroxyacyl-CoA deficiency (Laboratory tests: Hypoglycemia with low ketone levels, elevated transaminases, CK, elevated CK-MB and LDH, analysis of blood acylcarnitine profile, etc.)
- Pyruvate carboxylase deficiency (Laboratory tests: Hypoglycemia with low ketone levels, elevated transaminases, CK, elevated CK-MB and LDH, analysis of blood acylcarnitine profile, etc.)
- Porphyria (Laboratory tests: Sunlight test of urinary porphobilinogen)
- Acute pancreatitis
- Liver failure
- Pregnancy
- Relative contraindications:
- Patients who cannot maintain adequate nutrition (Fasting blood glucose < 2.8 mmol/L, blood ketone > 0.5 mmol/L) (15) Any other situations that the investigator considers unsuitable for participating in this study; (16)Currently participating in other investigational product/device for treatment or participating in other clinical trials for treatment purposes.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: An Exploratory Study for Evaluating the Efficacy, Safety and Tolerability of JT821 in the Intervention of Behavioral Variant Frontotemporal Dementia
This study is an exploratory clinical research on the use of JT821 (a ketogenic diet formulation) for the treatment of patients with behavioral variant frontotemporal dementia (bvFTD), aiming to evaluate the effectiveness, safety, and tolerability of JT821 in the intervention of bvFTD.
The ketogenic diet (KD) is a low-carbohydrate, adequate protein and high-fat diet. KD was shown to be effective in treating different neurodegenerative diseases.
Read the detailed description
This is an exploratory clinical research planned to include 20 subjects diagnosed with behavioral variant frontotemporal dementia (bvFTD). The primary aim of the study is to evaluate the tolerability, efficacy, and safety of JT821 in the treatment of bvFTD.
All subjects will undergo a 1-week product titration period before entering a 12 week treatment period.
Efficacy assessments will be conducted at week 4 and week 12 during the treatment period, utilizing the Montreal Cognitive Assessment (MoCA), the Mini-Mental State Examination (MMSE), and the Clinical Dementia Rating (CDR) scale to assesses the overall cognitive function of the subjects. Additionally, the Frontal Assessment Battery (FAB) will evaluate the executive functions of the frontal lobes; the Neuropsychiatric Inventory (NPI) and the Frontal Behavioral Inventory (FBI) assess the neuropsychiatric and behavioral symptoms of patients; the Boston Naming Test (BNT) and the Verbal Fluency Test (VFT) assess language functions.
Safety evaluation will include the vital signs, laboratory tests (fasting blood glucose, blood ketone levels (β-hydroxybutyrate), urinalysis, complete blood count, fasting lipid profile, liver and kidney function), as well as the recording of any adverse events.
Subjects may withdraw from the study at any time. If subjects experience a serious adverse event, become pregnant, are lost to follow-up, show poor adherence, or if the subject or their legal guardian actively requests to withdraw or retracts informed consent, they may be withdrawn based on the investigator's determination. The sponsor reserves the right to terminate the study at any time for special reasons (such as major safety concerns, force majeure, etc.).
A safety follow-up will be conducted two weeks after the termination of treatment.
- Being tested
- Ketogenic diet
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Ketogenic dietDietary supplement
Ketogenic diet
| Study group | Role | What they receive |
|---|---|---|
| Ketogenic diet | Experimental | The subjects initially enter the screening phase (≤ 2 weeks); they undergo the titration period (1 week), gradually titrating to the maximum dose stipulated in the protocol or the maximum tolerable dose for the subject; during the treatment period (12 weeks), but if intolerance emerges during the treatment, the subject can revert to the previous tolerated dose for continued treatment.
The dosage was titrated incrementally until reaching the maximum daily dose of 30g * 3 meals a day as stipulated in the protocol or the maximum tolerable daily dose for the subject. After entering the treatment period (from week 2 to week 13), this dose was maintained for 12 weeks. Receives: Dietary Supplement: Ketogenic diet |
What is being measured
The primary outcome is the main question the study is designed to answer.
Montreal Cognitive Assessment (MoCA)
After 4 and 12 weeks of treatment, the changes in MoCA scores compared to the baseline MoCA evaluates various cognitive domains including attention, executive functions, memory, language, visuospatial skills, abstraction, calculation, and orientation. It takes about 10 minutes to administer and is scored out of 30 points, with a score of 26 or above considered normal.
Measured: After 4 and 12 weeks of treatment, changes in MoCa scores relative to baseline.
Mini-Mental State Examination (MMSE)
After 4 and 12 weeks of treatment, changes in MMSE score compared to the baseline. MMSE tests cognitive function in five areas: orientation, registration, attention and calculation, recall, and language. It consists of 11 questions, with total score ranging from 0-30 points. Lower score indicate greater cognitive impairment.
Measured: After 4 and 12 weeks of treatment, changes in MMSE score relative to baseline.
Clinical Dementia Rating (CDR) scale
After 4 and 12 weeks of treatment, changes in CDR score compared to the baseline. CDR assess the progression of dementia, it evaluates six cognitive domains: memory, orientation, judgment/problem solving, community affairs, home and hobbies, and personal care. The CDR provides both a global score and a "Sum of Boxes" score, which ranges from 0 to 18. Higher scores on the CDR indicate more severe dementia.
Measured: After 4 weeks and 12 weeks of treatment, changes relative to baseline
Frontal Assessment Battery (FAB)
After 4 and 12 weeks of treatment, changes in FAB score compared to the baseline. FAB assess frontal lobe functions, with tasks evaluating conceptualization, mental flexibility, motor programming, sensitivity to interference, inhibitory control, and environmental autonomy. The total maximum score is 18, with higher scores indicating better performance.
Measured: After 4 weeks and 12 weeks of treatment, changes relative to baseline
Neuropsychiatric Inventory (NPI)
After 4 and 12 weeks of treatment, changes in NPI score compared to the baseline It evaluates 12 domains including delusions, hallucinations, and apathy, with severity rated from 1 to 3 and frequency from 1 to 4. Higher scores indicate more severe symptoms.
Measured: After 4 weeks and 12 weeks of treatment, changes relative to baseline
Frontal Behavioral Inventory (FBI)
After 4 and 12 weeks of treatment, changes in FBI score compared to the baseline. The FBI is a 24-item caregiver questionnaire that measures behaviors associated with frontal lobe dysfunction, such as apathy and disinhibition. It uses a four-point scale for each item and is scored based on caregiver responses, with higher scores indicating greater impairment.
Measured: After 4 weeks and 12 weeks of treatment, changes relative to baseline
Boston Naming Test (BNT)
After 4 and 12 weeks of treatment, changes in BNT score compared to the baseline. BNT score changes from baseline after 4 and 12 weeks of treatment. The BNT is a quantitative measure of confrontation naming ability, consisting of 60 line drawings of objects. It assesses dysnomia and is sensitive in detecting naming difficulties compared to physical object naming.
Measured: After 4 weeks and 12 weeks of treatment, changes relative to baseline
Verbal Fluency Test (VFT)
After 4 and 12 weeks of treatment, changes in VFT score compared to the baseline.The VFT involves generating words within a category or starting with a specific letter within a time limit. It measures executive functions and language use, with fewer words indicating potential cognitive deficits.
Measured: After 4 weeks and 12 weeks of treatment, changes relative to baseline
Secondary outcomes (1)
Comparison of the variations in blood ketone values relative to baseline during the treatment period
This measure compares the variations in blood ketone levels relative to the baseline during the treatment period. It also examines the influence of blood ketone levels on cognitive function; higher blood ketone levels are associated with improved cognitive function and therapeutic efficacy.
Measured: During the 12-week treatment course
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Jan 2025
- Study start10 Feb 2025 (estimated)
- Primary completion31 Aug 2025 (estimated)
- Study completion31 Oct 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Behavioral Variant Frontotemporal DementiaStudies of the same condition, open and under way.
- More trials run by Xuanwu Hospital, BeijingThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Single Group Assignment,
- Masking
- None (open label)
- Enrolment
- 3 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Xuanwu Hospital, Beijing
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06761729
- Sponsor's protocol ID
- XWYY-bvFTD-01
- Acronym
- JT821
- Status last verified
- Jan 2025
- First submitted
- 24 Dec 2024
- Last updated
- 10 Feb 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Feb 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Exploratory Study for Evaluating the Efficacy, Safety and Tolerability of JT821 in the Intervention of Behavioral Variant Frontotemporal Dementia
- ClinicalTrials.gov ID
- NCT06761729
- Acronym / sponsor ID
- JT821 / XWYY-bvFTD-01
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 3 participants (estimated)
- Lead sponsor
- Xuanwu Hospital, BeijingUniversity, hospital or other
- Study start
- 10 Feb 2025 (estimated)
- Primary completion
- 31 Aug 2025 (estimated)
- Study completion
- 31 Oct 2025 (estimated)
- First posted
- 7 Jan 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is an exploratory clinical research on the use of JT821 (a ketogenic diet formulation) for the treatment of patients with behavioral variant frontotemporal dementia (bvFTD), aiming to evaluate the effectiveness, safety, and tolerability of JT821 in the intervention of bvFTD.
The ketogenic diet (KD) is a low-carbohydrate, adequate protein and high-fat diet. KD was shown to be effective in treating different neurodegenerative diseases.
Detailed description
This is an exploratory clinical research planned to include 20 subjects diagnosed with behavioral variant frontotemporal dementia (bvFTD). The primary aim of the study is to evaluate the tolerability, efficacy, and safety of JT821 in the treatment of bvFTD.
All subjects will undergo a 1-week product titration period before entering a 12 week treatment period.
Efficacy assessments will be conducted at week 4 and week 12 during the treatment period, utilizing the Montreal Cognitive Assessment (MoCA), the Mini-Mental State Examination (MMSE), and the Clinical Dementia Rating (CDR) scale to assesses the overall cognitive function of the subjects. Additionally, the Frontal Assessment Battery (FAB) will evaluate the executive functions of the frontal lobes; the Neuropsychiatric Inventory (NPI) and the Frontal Behavioral Inventory (FBI) assess the neuropsychiatric and behavioral symptoms of patients; the Boston Naming Test (BNT) and the Verbal Fluency Test (VFT) assess language functions.
Safety evaluation will include the vital signs, laboratory tests (fasting blood glucose, blood ketone levels (β-hydroxybutyrate), urinalysis, complete blood count, fasting lipid profile, liver and kidney function), as well as the recording of any adverse events.
Subjects may withdraw from the study at any time. If subjects experience a serious adverse event, become pregnant, are lost to follow-up, show poor adherence, or if the subject or their legal guardian actively requests to withdraw or retracts informed consent, they may be withdrawn based on the investigator's determination. The sponsor reserves the right to terminate the study at any time for special reasons (such as major safety concerns, force majeure, etc.).
A safety follow-up will be conducted two weeks after the termination of treatment.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Single Group Assignment,
| Arm | Type | Receives |
|---|---|---|
| Ketogenic diet | Experimental | Dietary Supplement: Ketogenic dietThe subjects initially enter the screening phase (≤ 2 weeks); they undergo the titration period (1 week), gradually titrating to the maximum dose stipulated in the protocol or the maximum tolerable dose for the subject; during the treatment period (12 weeks), but if intolerance emerges during the treatment, the subject can revert to the previous tolerated dose for continued treatment. The dosage was titrated incrementally until reaching the maximum daily dose of 30g * 3 meals a day as stipulated in the protocol or the maximum tolerable daily dose for the subject. After entering the treatment period (from week 2 to week 13), this dose was maintained for 12 weeks. |
Who may qualify
- Ages
- 45 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Subject is between the ages of 45 - 70;
- Meetting the diagnostic criteria for "probable bvFTD published by the International bvFTD Standards Consortium in 2011;
- Subjects must not undergo any drug adjustment treatment for 2 months prior to the enrollment and during the enrollment period ;
- Subjects must sign a written informed consent form prior to the screening visit examination. If the subject cannot sign due to limited cognitive ability or other reasons, the signature may be left blank, and the rationale must be stated. The legal guardian should provide the reason, sign the name, date, and time in the reason description area, and also sign the name, date, and time in the legal guardian column.
- Subject is between the ages of 45 - 70;
Key exclusion criteria (33 listed)
- Dementia caused by other factors: Alzheimer's Disease，vascular dementia, central nervous system infections (such as AIDS, syphilis, etc.), Huntington's disease and Parkinson's disease, Lewy body dementia, traumatic brain injury dementia, other physical and chemical factors (such as drug poisoning, alcohol poisoning, carbon monoxide poisoning, etc.), significant somatic diseases (such as hepatic encephalopathy, pulmonary etc.), intracranial space-occupying lesions (such as subdural hematoma, brain tumors), endocrine system disorders (such as thyroid diseases, parathyroid diseases) and dementia caused by vitamin deficiency or any other known causes;
- Having a low-carb diet , ketogenic diet, or vegan diet within 3 months before the screening visit or being currently doing.
- Patients diagnosed with schizophrenia spectrum disorder ,bipolar disorder, moderate to severe depression or delirium according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).
- Abnormal laboratory tests at screening visit and baseline: including liver function tests (alanine aminotransferase [ALT], aspartate aminotransferase [AST]) exceeding twice the upper limit of normal; and renal function (creatinine [Cr]) exceeding 1.5 times the upper limit of normal. Slight exceedances that are not clinically significance, as judged by the investigator, may not be excluded;
- Fasting triglycerides ≥ 5.7 mmol/L or total cholesterol ≥ 10.34 mmol/L at the screening visit and baseline;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Ketogenic dietKetogenic diet | Dietary supplement | Ketogenic diet |
Primary outcome
Montreal Cognitive Assessment (MoCA)
Time frame: After 4 and 12 weeks of treatment, changes in MoCa scores relative to baseline.
After 4 and 12 weeks of treatment, the changes in MoCA scores compared to the baseline MoCA evaluates various cognitive domains including attention, executive functions, memory, language, visuospatial skills, abstraction, calculation, and orientation. It takes about 10 minutes to administer and is scored out of 30 points, with a score of 26 or above considered normal.
Mini-Mental State Examination (MMSE)
Time frame: After 4 and 12 weeks of treatment, changes in MMSE score relative to baseline.
After 4 and 12 weeks of treatment, changes in MMSE score compared to the baseline. MMSE tests cognitive function in five areas: orientation, registration, attention and calculation, recall, and language. It consists of 11 questions, with total score ranging from 0-30 points. Lower score indicate greater cognitive impairment.
Clinical Dementia Rating (CDR) scale
Time frame: After 4 weeks and 12 weeks of treatment, changes relative to baseline
After 4 and 12 weeks of treatment, changes in CDR score compared to the baseline. CDR assess the progression of dementia, it evaluates six cognitive domains: memory, orientation, judgment/problem solving, community affairs, home and hobbies, and personal care. The CDR provides both a global score and a "Sum of Boxes" score, which ranges from 0 to 18. Higher scores on the CDR indicate more severe dementia.
Frontal Assessment Battery (FAB)
Time frame: After 4 weeks and 12 weeks of treatment, changes relative to baseline
After 4 and 12 weeks of treatment, changes in FAB score compared to the baseline. FAB assess frontal lobe functions, with tasks evaluating conceptualization, mental flexibility, motor programming, sensitivity to interference, inhibitory control, and environmental autonomy. The total maximum score is 18, with higher scores indicating better performance.
Neuropsychiatric Inventory (NPI)
Time frame: After 4 weeks and 12 weeks of treatment, changes relative to baseline
After 4 and 12 weeks of treatment, changes in NPI score compared to the baseline It evaluates 12 domains including delusions, hallucinations, and apathy, with severity rated from 1 to 3 and frequency from 1 to 4. Higher scores indicate more severe symptoms.
Frontal Behavioral Inventory (FBI)
Time frame: After 4 weeks and 12 weeks of treatment, changes relative to baseline
After 4 and 12 weeks of treatment, changes in FBI score compared to the baseline. The FBI is a 24-item caregiver questionnaire that measures behaviors associated with frontal lobe dysfunction, such as apathy and disinhibition. It uses a four-point scale for each item and is scored based on caregiver responses, with higher scores indicating greater impairment.
Boston Naming Test (BNT)
Time frame: After 4 weeks and 12 weeks of treatment, changes relative to baseline
After 4 and 12 weeks of treatment, changes in BNT score compared to the baseline. BNT score changes from baseline after 4 and 12 weeks of treatment. The BNT is a quantitative measure of confrontation naming ability, consisting of 60 line drawings of objects. It assesses dysnomia and is sensitive in detecting naming difficulties compared to physical object naming.
Verbal Fluency Test (VFT)
Time frame: After 4 weeks and 12 weeks of treatment, changes relative to baseline
After 4 and 12 weeks of treatment, changes in VFT score compared to the baseline.The VFT involves generating words within a category or starting with a specific letter within a time limit. It measures executive functions and language use, with fewer words indicating potential cognitive deficits.
1 secondary outcome
Comparison of the variations in blood ketone values relative to baseline during the treatment period
Time frame: During the 12-week treatment course
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Feb 2025.
- Individual participant dataSharing planned: No
Related trials for Behavioral Variant Frontotemporal Dementia
RecruitingObservational study
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP)
RecruitingPhase 1/2
A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)
Frontotemporal Dementia, FTD
Active, not recruitingPhase 2
Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia
Nonfluent Variant Primary Progressive Aphasia (nfvPPA)
RecruitingObservational study
Premorbid Personality Profile of Patients With Cognitive and Behavioral Disorders
Behavioral Variant of Frontotemporal Disorder (bvFTD), Phenocopy Frontotemporal Dementia (phFTD)
Enrolling by invitation
Targeted Transcranial Magnetic Stimulation to Improve Language and Speech in Patients With Primary Progressive Aphasia
Primary Progressive Aphasia(PPA)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
A study testing Ketogenic diet in people with Behavioral Variant Frontotemporal Dementia, run by Xuanwu Hospital, Beijing.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 33 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 10 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Longfei Jia, Dr. (0086-10 - 83199449, jialongfei@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Montreal Cognitive Assessment (MoCA) (time frame: After 4 and 12 weeks of treatment, changes in MoCa scores relative to baseline.). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Feb 2025.